{
    "clinical_study": {
        "@rank": "163393", 
        "brief_summary": {
            "textblock": "The goal of this research is to see if giving the drug SCH66336 by mouth can improve the\n      disease in patients with chronic or accelerated phase CML. The safety of this treatment will\n      also be studied."
        }, 
        "brief_title": "Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)", 
        "completion_date": {
            "#text": "May 2004", 
            "@type": "Actual"
        }, 
        "condition": "Myelogenous Leukemia, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Chronic Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "Objectives for this study are two-fold:\n\n        1. To determine the efficacy of SCH66336 in patients with chronic phase and accelerated\n           phase CML in relation to response rate, duration of response, and survival.\n\n        2. To assess the toxicity of SCH66366 in these patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Diagnosis of Philadelphia chromosome (Ph) -positive CML in  chronic or accelerated\n             phase;\n\n          -  Failure to respond to or intolerance to imatinib mesylate (Gleevec);\n\n          -  Age >/= 16 years;\n\n          -  Life expectancy of >/= 2 months;\n\n          -  Performance status 2 or better (Zubrod);\n\n          -  Adequate renal and hepatic functions (creatinine and bilirubin </= 2 mg/dl);\n\n          -  Adequate cardiac function;\n\n          -  Not candidates for or have refused allogeneic transplantation;\n\n          -  Patients should not be receiving azoles (ketoconazole, itraconazole, fluconazole),\n             macrolides, HIV protease inhibitors, cyclosporin or anti-seizure drugs\n             (phenobarbital, phenytoin, carbamazepine), rifampin or isoniazid."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "13", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 3, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00038597", 
            "org_study_id": "DM01-072"
        }, 
        "intervention": {
            "intervention_name": "SCH66336", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Philadelphia chromosome positive CML", 
            "Myelogenous Leukemia, Chronic, Chronic Phase", 
            "Myelogenous Leukemia, Chronic, Accelerated Phase"
        ], 
        "lastchanged_date": "January 20, 2012", 
        "link": {
            "description": "UT MD Anderson Cancer Center Website", 
            "url": "http://www.mdanderson.org"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "MDAnderson Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)", 
        "overall_official": {
            "affiliation": "UT MD Anderson Cancer Center", 
            "last_name": "Jorge Cortes, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2004", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00038597"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "M.D. Anderson Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "M.D. Anderson Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2001", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2012"
    }, 
    "geocoordinates": {
        "MDAnderson Cancer Center": "29.76 -95.369"
    }
}